Deepak Sharma

Dr. Deepak Sharma

School of Medicine Center for RNA Science and Therapeutics, Department of Biochemistry, Case Western Reserve University, 10900, Euclid Avenue, Cleveland, OH 44106, USA
orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 April 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
Deepak SharmaDeepak Sharma
Deepak Sharma
DADarbaz Adnan
Darbaz Adnan
MAMostafa K. Abdel-Reheem
Mostafa K. Abdel-Reheem
RARon C. Anafi
Ron C. Anafi
DLDaniel D. Leary
Daniel D. Leary
FBFaraz Bishehsari
Faraz Bishehsari
Pancreatic ductal adenocarcinoma (PDA) is a lethal cancer characterized by a poor outcome and an increasing incidence. A significant majority (>80%) of newly diagnosed cases are deemed unresectable, leaving chemotherapy as the sole viable option, though with only moderate success. This necessitates the identification of improved therapeutic options for PDA. We hypothesized that there are temporal variations in cancer-relevant processes within PDA tumors, offering insights into the optimal timing of drug administration — a concept termed chronotherapy. In this study, we explored the presence of the circadian transcriptome in PDA using patient-derived organoids and validated these findings by comparing PDA data from The Cancer Genome Atlas with noncancerous healthy pancreas data from GTEx. Several PDA-associated pathways (cell cycle, stress response, Rho GTPase signaling) and cancer driver hub genes ( EGFR and JUN ) exhibited a cancer-specific rhythmic pattern intricately linked to the circadian clock. Through the integration of multiple functional measurements for rhythmic cancer driver genes, we identified top chronotherapy targets and validated key findings in molecularly divergent pancreatic cancer cell lines. Testing the chemotherapeutic efficacy of clinically relevant drugs further revealed temporal variations that correlated with drug-target cycling. Collectively, our study unravels the PDA circadian transcriptome and highlights a potential approach for optimizing chrono-chemotherapeutic efficacy.